Principal Financial Group
NKTR icon

Principal Financial Group’s Nektar Therapeutics NKTR Stock Holding History

Principal Financial Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-764
Closed -$7.79K – 2290
2025
Q1 		$7.79K Buy
764
+46
+6% +$601 ﹤0.01% 2165
2024
Q4 		$10K Sell
718
-112
-13% -$1.98K ﹤0.01% 2204
2024
Q3 		$16.2K Sell
830
-337
-29% -$6.42K ﹤0.01% 2212
2024
Q2 		$21.7K Sell
1,167
-2,197
-65% -$46.3K ﹤0.01% 2335
2024
Q1 		$47.1K Sell
3,364
-103
-3% -$1.08K ﹤0.01% 2351
2023
Q4 		$29.4K Sell
3,467
-386
-10% -$2.92K ﹤0.01% 2366
2023
Q3 		$34.4K Buy
3,853
+317
+9% +$3.05K ﹤0.01% 2375
2023
Q2 		$30.5K Sell
3,536
-73,859
-95% -$788K ﹤0.01% 2391
2023
Q1 		$816K Sell
77,395
-1,125
-1% -$34K ﹤0.01% 1880
2022
Q4 		$2.66M Buy
78,520
+214
+0.3% +$10.4K ﹤0.01% 1709
2022
Q3 		$3.76M Buy
78,306
+356
+0.5% +$21.2K ﹤0.01% 1586
2022
Q2 		$4.44M Sell
77,950
-5,757
-7% -$363K ﹤0.01% 1593
2022
Q1 		$6.77M Sell
83,707
-413
-0.5% -$61.1K ﹤0.01% 1544
2021
Q4 		$17M Buy
84,120
+39,324
+88% +$8.53M 0.01% 1061
2021
Q3 		$12.1M Sell
44,796
-248
-0.6% -$59.6K 0.01% 1302
2021
Q2 		$11.6M Buy
45,044
+660
+1% +$183K 0.01% 1352
2021
Q1 		$13.3M Buy
44,384
+6,514
+17% +$2.03M 0.01% 1228
2020
Q4 		$9.66M Buy
37,870
+38
+0.1% +$9.82K 0.01% 1251
2020
Q3 		$9.41M Sell
37,832
-1,121
-3% -$353K 0.01% 1117
2020
Q2 		$13.5M Buy
38,953
+1,826
+5% +$570K 0.01% 870
2020
Q1 		$9.94M Sell
37,127
-14,388
-28% -$4.45M 0.01% 909
2019
Q4 		$16.7M Buy
51,515
+33,364
+184% +$9.67M 0.01% 941
2019
Q3 		$4.96M Sell
18,151
-468
-3% -$172K ﹤0.01% 1521
2019
Q2 		$9.94M Sell
18,619
-708
-4% -$355K 0.01% 1222
2019
Q1 		$9.74M Buy
19,327
+112
+0.6% +$66.4K 0.01% 1243
2018
Q4 		$9.47M Buy
19,215
+176
+0.9% +$106K 0.01% 1211
2018
Q3 		$17.4M Buy
19,039
+2,626
+16% +$2.24M 0.02% 956
2018
Q2 		$12M Sell
16,413
-8,025
-33% -$9.25M 0.01% 1192
2018
Q1 		$39M Sell
24,438
-69,312
-74% -$89.3M 0.04% 474
2017
Q4 		$84M Sell
93,750
-3,450
-4% -$2.04M 0.08% 297
2017
Q3 		$35M Sell
97,200
-4,797
-5% -$1.5M 0.03% 504
2017
Q2 		$29.9M Buy
101,997
+4
+0% +$1.16K 0.03% 568
2017
Q1 		$35.9M Buy
101,993
+2,723
+3% +$612K 0.04% 444
2016
Q4 		$18.3M Buy
99,270
+10,731
+12% +$2.18M 0.02% 753
2016
Q3 		$22.8M Buy
88,539
+3,433
+4% +$884K 0.03% 583
2016
Q2 		$18.2M Buy
85,106
+1,482
+2% +$331K 0.03% 671
2016
Q1 		$17.2M Buy
83,624
+3,077
+4% +$591K 0.03% 657
2015
Q4 		$20.4M Buy
80,547
+3,767
+5% +$775K 0.03% 559
2015
Q3 		$12.6M Buy
76,780
+2,371
+3% +$419K 0.02% 780
2015
Q2 		$14M Buy
74,409
+55,012
+284% +$9.47M 0.02% 766
2015
Q1 		$3.2M Buy
19,397
+261
+1% +$53.6K ﹤0.01% 1544
2014
Q4 		$4.45M Sell
19,136
-1,299
-6% -$278K 0.01% 1435
2014
Q3 		$3.7M Buy
20,435
+336
+2% +$64.3K 0.01% 1485
2014
Q2 		$3.87M Sell
20,099
-604
-3% -$107K 0.01% 1508
2014
Q1 		$3.76M Buy
20,703
+19,007
+1,121% +$3.76M 0.01% 1491
2013
Q4 		$289K Sell
1,696
-366
-18% -$59K ﹤0.01% 2015
2013
Q3 		$323K Sell
2,062
-331
-14% -$61.2K ﹤0.01% 1938
2013
Q2 		$415K Buy
+2,393
New +$367K ﹤0.01% 1860

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Principal Financial Group's NKTR Position: Q2 2025 in Review

Principal Financial Group sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 764 shares — an estimated $7.79K sold.

Principal Financial Group first reported a position in NKTR in Q2 2013 and held it in 48 quarters. The position peaked at $84M in Q4 2017. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • Principal Financial Group reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Principal Financial Group sold 764 Nektar Therapeutics shares in Q2 2025, an estimated $7.79K.
  • Principal Financial Group first reported a position in Nektar Therapeutics in Q2 2013 and held it in 48 quarters.
  • Principal Financial Group's Nektar Therapeutics position peaked at $84M in Q4 2017.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on Principal Financial Group's 13F filing for Q2 2025, filed 8 Aug 2025.